Pfizer, which previously backed Reflexion's $11.6m series A round in 2014, has returned to increase its commitment in the medical device manufacturer.

The genomics technology company will act as majority limited partner for the independently managed Illumina Ventures, providing the cash over a 10-year period.

Manchester University has licensed optogenetic gene therapy to Acucela to develop possible treatments for diseases such as Retinitis Pohmentosa, which causes gradual loss of sight.

Geneva spinout Amal Therapeutics moves on with the development of its potential colorectal cancer therapy as it raises $3.1m in series A funding.

Chronic disorder management platform Livongo Health has attracted Blue Cross Blue Shield of Massachusetts, Merck and Wanxiang America Corporation for its series C round.

Intellia Therapeutics, which has raised $85m in under 18 months from backers including Novartis, has signed a collaboration agreement with Regeneron and filed for a $120m IPO.

The round featured corporate-backed venture firm Lux Capital and will support completion of phase 3 trials for a treatment aimed at dry eye disease.

Boehringer Ingelheim returned to reinvest in the in-vitro diagnostics technology company, taking its overall funding to more than $50m as it gears up to release its product.

Forbion Capital Partners has closed its third main fund at $208m, attracting commitments from Charles River Laboratories, Knight Therapeutics and unnamed insurance providers.